Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

Completed · Phase 3 · Has a placebo group

Conditions studied: Lymphoma, Non-Hodgkin

In brief

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous transplantation.

Key facts

Study ID
NCT00103610
Run by
Genzyme, a Sanofi Company
People needed
298
Starts
2005-01-01
Expected to finish
2007-12-01
Last updated by the study team
2014-03-13

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.